Type 2 diabetes and HbA1c targets

Prescrire International

Volumn 17, Issue 98, 2008, Pages 254-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TARGETING; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ALBUMINURIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 66149168543     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Prescrire Editorial Staff "Managing type 2 diabetes" Prescrire Int 2001; 10 (55): 158.
2. Prescrire Rédaction "Traitement médicamenteux du diabète de type 2; l'Afssaps et la HAS font la part belle aux médicaments sans tenir compte des réalités cliniques" Rev Prescrire 2007; 27 (283): 389.
3. Prescrire Editorial Staff "Higher type 2 diabetes-related mortality when HbA1c levels are too low" Prescrire Int 2008; x27 (97): 213.
4. The Action to Control Cardiovascular Risk in Diabetes (Accord) Study Group "Effects of intensive glucose lowering in type 2 diabetes" N Engl J Med 2008; 358: 2545-2559.
5. The Advance Collaborative Group "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes" N Engl J Med 2008; 358: 2560-2572.
6. Gæde P et al. "Effect of a multifactorial intervention on mortality in type 2 diabetes" N Engl J Med 2008; 358: 580-591.